1. Academic Validation
  2. PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway

PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway

  • Am J Transl Res. 2019 Aug 15;11(8):5134-5149.
Yinci Zhang 1 Chunmei Xie 2 Amin Li 1 Xueke Liu 1 Yingru Xing 1 Jing Shen 1 Zhen Huo 1 Shuping Zhou 3 Xinkuang Liu 3 Yinghai Xie 3 Weiya Cao 1 Yongfang Ma 1 Ruyue Xu 1 Shiyu Cai 1 Xiaolong Tang 1 Dong Ma 4
Affiliations

Affiliations

  • 1 Medcial School, Anhui University of Science & Technology Huainan 232001, China.
  • 2 Department of Blood Transfusion, Guangzhou 8th People's Hospital, Guangzhou Medical University Guangzhou 510100, China.
  • 3 First Affiliated Hospital, Anhui University of Science & Technology Huainan 232001, China.
  • 4 Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Jinan University Guangzhou 510632, China.
PMID: 31497229
Abstract

Oxaliplatin resistance limits its effectiveness in the treatment of hepatocellular carcinoma (HCC). Abnormal activation of the PI3K/Akt/mTOR pathway has been associated with decreased survival of HCC patients, anti-apoptosis after chemotherapeutic drug-induced DNA damage, and chemoresistance. In this research, we evaluated the effect of the dual PI3K/mTOR Inhibitor, PKI-587, on the sensitivity of oxaliplatin in HCC. Two HCC cell lines (HepG2 and SK-Hep1) were used to analyze PKI-587 for DNA damage response, cell proliferation, clonogenic survival, cell cycle and Apoptosis after oxaliplatin treatment. A HepG2 tumor-bearing model was used to assess the in vivo effects of the combination of the two compounds. In HCC cells, oxaliplatin stably activated the PI3K/Akt/mTOR pathway, including up-regulation of p-Akt (Ser473), p-mTOR (Ser2448), p-mTOR (Ser2481), p-elF4EBP1, and p-S6K1, and activated the DNA damage repair pathways (non-homologous end joining (NHEJ) and homologous recombination (HR)), up-regulation of p-DNAPKcs (Ser2056), p-ATM (Ser1981), and p-ATR (Ser428), which were attenuated by PKI-587. Compared with oxaliplatin alone, the combination of PKI-587 and oxaliplatin increased the number of γ-H2AX/cells, decreased proliferation of cells, and an increased the percentage of G0/G1 phase cells and apoptotic cells. In vivo, the combination of oxaliplatin with PKI-587 inhibited tumor growth. Anti-tumor effects were associated with induction of mitochondrial Apoptosis and inhibition of phosphorylation of mTOR, Akt and γ-H2AX. We conclude that PKI-587 enhances chemosensitivity of oxaliplatin in HCC through suppressing the PI3K/Akt/mTOR signalling pathway and inhibiting the DNA damage repair pathway. The combination of PKI-587 and oxaliplatin appears to be a promising regimen for the treatment of HCC.

Keywords

Oxaliplatin; PI3K/mTOR; PKI-587; hepatocellular carcinoma; homologous recombination; nonhomologous end joining.

Figures
Products